OneMedNet Corporation ONMD
- Market cap
- $41.8M
- P/E
- 0.0×
Follow ONMD
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 9.81 | 10.07 | 0.68 | 0.42 | 0.30 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 10.20 | 10.56 | 13.51 | 3.37 | 4.22 |
High Price
|
|||
| — | — | — | — | — | 2 | 2 | 20 | 24 | 23 |
Employees
|
|||
| — | — | — | — | — | 0 | 1 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | 1 | 1 | 1 | 1 |
Revenue
|
|||
| — | — | — | — | — | — | (31.22%) | (12.63%) | (43.70%) | (37.01%) |
Gross Margin
|
|||
| — | — | — | — | — | 5 | (30) | (34) | (10) | (3) |
EBT
|
|||
| — | — | — | — | — | 0.00% | (2,639.55%) | (3,306.76%) | (1,574.96%) | (206.03%) |
EBT Margin
|
|||
| — | 0 | — | — | — | 5 | (30) | (34) | (10) | (3) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | 0.00 | 0.29 | 0.14 | 0.02 | 0.03 |
Revenue/Sh
|
|||
| — | — | — | — | — | 1.56 | (7.66) | (4.65) | (0.36) | (0.06) |
Earnings/Sh
|
|||
| — | — | — | — | — | (0.11) | (1.18) | (0.66) | (0.25) | (0.17) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | (0.11) | (1.20) | (0.66) | (0.25) | (0.17) |
Free CF/Sh
|
|||
| — | — | — | — | — | (2.61) | (6.63) | (1.85) | (0.57) | (0.07) |
Book Value/Sh
|
|||
| — | — | — | — | — | 3 | 4 | 7 | 28 | 45 |
Shares
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 5.27 | 59.39 | 36.06 |
PS Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 9.07 | 63.06 | 35.97 |
EV/Sales
|
|||
| — | — | — | — | — | — | (9.08) | (1.89) | (5.79) | (6.50) |
EV/FCF
|
|||
| — | — | — | — | — | 0 | (5) | (5) | (7) | (8) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | 0 | (5) | (5) | (7) | (8) |
FCF
|
|||
| — | — | — | — | — | 0 | (26) | (13) | (16) | (3) |
Working Cap'
|
|||
| — | — | — | — | — | — | 2 | 3 | 4 | 1 |
Total Debt
|
|||
| — | — | — | — | — | 0 | 1 | 3 | 1 | 0 |
Net Debt
|
|||
| — | — | — | — | — | (9) | (26) | (13) | (16) | (3) |
Sh' Equity
|
|||
| — | — | — | — | — | 4.36% | (200.67%) | (3,853.96%) | (483.37%) | (95.30%) |
ROA
|
|||
| — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | 10.26% | 253.13% | 117.61% | 68.92% | 29.62% |
ROE
|
|||
OneMedNet Corporation peers in Health Information Services
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DRIO DarioHealth Corp. | $66.3M | 0.0× | Compare |
| BEAT HeartBeam, Inc. | $21.7M | 0.0× | Compare |
| CCLD CareCloud, Inc. | $87.5M | 29.4× | Compare |
| RNLXY Renalytix plc - Sponsored ADR | $17.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BFRG Bullfrog AI Holdings Inc. | $13.5M | 0.0× | Compare |
| HCAT Health Catalyst, Inc. | $131.0M | 0.0× | Compare |
| LFMD LifeMD, Inc. | $140.3M | 0.0× | Compare |
| DH Definitive Healthcare Corp. | $146.3M | 0.0× | Compare |
OneMedNet Corporation (ONMD) key facts
- OneMedNet Corporation (ONMD) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- OneMedNet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 111.4% from fiscal 2024.
- As of September 25, 2026, ONMD traded at $0.65, a market capitalization of $41.8 million.
- Return on equity was 29.6% and debt-to-equity -0.20.
OneMedNet Corporation (ONMD) Latest News
25 Sep
OneMedNet Corporation will implement a 1-for-10 reverse stock split, effective Sept. 29, 2026, to restore the stock price for Nasdaq Capital Market compliance and broaden investor interest. At the effective time, ten existing shares become one, reducing outstanding common shares from about 59,286,450 to roughly 5,928,645; authorized shares remain unchanged. Fractional shares will not be issued; any fractions will be rounded up. Post-split trading is expected to begin under the same ticker ONMD with the new CUSIP 68270C202. The reverse split will proportionately adjust equity incentive plans, including options, warrants, RSUs, and other instruments. Continental Stock Transfer & Trust Company is the exchange and transfer agent. The company highlights its iRWD platform delivering regulatory decision-grade, AI-ready Real-World Data from a network of over 2,300 sites and 90 million patient journeys; forward-looking statements accompany the release. A reverse split primarily affects share count and listing eligibility, with limited immediate impact on operations.
22 Sep
Atropos Health announced a major expansion of its Atropos Evidence Network, deepening collaborations with Norstella and Arcadia and adding new data partnerships with OneMedNet, to extend the network across clinical decision support, model training, and benchmark development. The federated network now spans more than 330 million U.S. patients, includes open and closed claims, 150 million+ EHR records (with clinical notes), and multimodal data such as imaging and omics linked to outcomes and mortality datasets. A privacy-first linkage approach and proprietary de-identification underlie regulatory-grade RWE capabilities. Applications span regulatory-grade RWE generation, HEOR, rapid commercial analytics, and AI model training to identify rare or undiagnosed populations and benchmark performance. The integration enables faster, cost-efficient queries and relies on RWFS, Atropos’ trust scoring. OneMedNet emphasizes eliminating access barriers with direct-source data for long-term subscriptions. Expands OneMedNet's data access and monetization opportunities within a major federated network, signaling potential revenue growth.
OneMedNet and Atropos Health announced a multi-year, subscription-based license to embed OneMedNet’s regulatory-grade, multimodal Real-World Data into Atropos’ evidence-generation platform. The 3-year deal allows Atropos customers to purchase OneMedNet data—derived from over 90 million patient journeys across 2,300 sites and 270 million studies—within Atropos workflows, expanding OneMedNet’s ARR and broadening its reach to health systems, biopharma, and researchers. Company executives say the partnership reduces data-access friction and delivers richer, decision-grade evidence, strengthening OneMedNet’s product offering as demand for multimodal RWD grows. The press release includes standard forward-looking language and risk disclosures. Multi-year, subscription-based arrangement with regulatory-grade, multimodal data expands recurring revenue and strengthens OneMedNet's long-term market position.
18 Sep
OneMedNet reports record bookings as faster fulfillment begins. Record bookings and faster fulfillment point to stronger demand and operational gains likely to lift near-term performance.
31 Aug
OneMedNet’s iRWD Platform enables rapid feasibility-to-delivery for a leading AI-driven drug development company. Platform deployment with AI drug developer indicates expanded reach in healthcare data applications.
28 Jul
OneMedNet Corporation secures over $11.5 million agreement to supply regulatory-grade real-world data for foundational AI model development. Major contract expands revenue and strengthens OneMedNet position supplying data for AI development.
10 Jun
OneMedNet secures over $3 million in new bookings, surpassing its full-year 2025 target via growth strategy execution. Exceeding full-year 2025 bookings target with over $3 million signals major revenue upside and improved market trajectory.
3 Jun
OneMedNet surpassed 90 million patient journeys and 270 million studies in its network. Network scale milestones support potential gains in market visibility and adoption for OneMedNet.
22 Apr
OneMedNet Corporation (ONMD) launches platform live with 80 million patient journeys and billions of records. Launching a massive dataset platform with 80 million patient journeys and billions of records marks a major strategic advancement in healthcare data services, poised to drive growth and investor interest.
6 Apr
OneMedNet Corporation announces strong 2025 financials and advances its AI-driven iRWD™ platform powered by Palantir Foundry, enabling conversational search on real-time medical data. Strong 2025 financial projections combined with AI platform advancements via Palantir Foundry represent major strategic enhancements driving ONMD's growth and competitive edge in healthcare data.
1 Apr
OneMedNet Corporation, Onco-Innovations, and Inka Health announced a collaboration to accelerate oncology drug development using OneMedNet's real-world data and AI technologies. The strategic partnership positions OneMedNet's real-world data platform at the forefront of AI-driven oncology innovation, likely boosting revenue potential and investor interest.
18 Mar
OneMedNet Corporation and Navidence announced a strategic collaboration to empower pharmaceutical companies with precision real-world data insights. Strategic collaboration with Navidence bolsters OneMedNet's real-world data capabilities for pharma, driving significant revenue potential and competitive positioning.
27 Feb
OneMedNet Corporation announces the next phase of commercial launch for its Real-World Data (RWD) Platform powered by Palantir Foundry. Commercial launch advancement of RWD platform with Palantir Foundry integration marks a major strategic move likely to boost ONMD's competitive position and investor sentiment.
26 Feb
OneMedNet Corporation (ONMD) partners with ViuHealth to significantly expand its autoimmune dataset scale, accelerating recurring revenue streams from life sciences and AI customers. Partnership enhances core dataset offerings and drives recurring revenue growth from high-value life sciences and AI sectors.
24 Feb
OneMedNet Corporation (ONMD) announces strategic neuro data partnership with Risorius to advance EEG-based digital biomarkers, leveraging ONMD's iRWD platform for AI-driven neuroscientific research. Strategic partnership expands ONMD's role in neuro data and AI biomarkers, driving innovation and potential revenue growth.
12 Feb
OneMedNet Corporation (ONMD) reported record bookings of $2.79 million for 2025, surpassing the previous year's figures by over 4.1 times. The company is accelerating its transition to a subscription-based model, indicating strong growth and demand for its services. Record bookings and a shift to subscription services suggest significant growth potential and positive market sentiment.
22 Jan
OneMedNet Corporation announced that real-world data has supported the FDA's 510(k) clearance of its AI-powered Scaida BrainCT-ICH software, which is designed to assist in the detection of intracerebral hemorrhage. This clearance marks a significant milestone for the company, enhancing its product offerings in the medical imaging sector and potentially improving patient outcomes in emergency settings. The FDA clearance of the AI-powered software is a significant regulatory achievement that could enhance OneMedNet's market position and product portfolio.
16 Jan
OneMedNet Corporation has launched a real-world data feed encompassing 1.5 million patients and 4 million encounters. This extensive dataset aims to enhance healthcare analytics and improve patient outcomes by providing valuable insights into real-world treatment patterns and outcomes. The introduction of a comprehensive real-world data feed is likely to significantly impact OneMedNet's market positioning and investor sentiment.
22 Dec
OneMedNet Corporation CEO Aaron Green has issued a letter to shareholders outlining the company's strategic vision and goals for 2025. The letter emphasizes growth initiatives, product development, and market expansion plans aimed at enhancing shareholder value and positioning the company for future success. The outlined strategic vision and growth initiatives are likely to significantly impact the company's future performance and investor sentiment.
10 Dec
OneMedNet Corporation (ONMD) reported strong momentum and excitement within the industry during the RSNA conference. The company showcased its innovative solutions aimed at enhancing medical imaging and data management. Attendees expressed enthusiasm about ONMD's advancements, indicating a positive reception and potential for future growth in the healthcare technology sector. Strong industry excitement and innovative solutions presented at a major conference suggest significant potential for future growth and market performance.
28 Nov
OneMedNet Corporation (ONMD) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect broader market trends or specific developments related to the company, potentially influencing its stock performance and investor sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and could affect the company's competitive positioning.
24 Nov
OneMedNet Corporation (ONMD) is set to unveil its innovative new platform at the RSNA 2025 conference. This platform aims to enhance medical imaging and data management, showcasing the company's commitment to advancing healthcare technology. The presentation is expected to attract significant attention from industry professionals and stakeholders, highlighting ONMD's role in transforming medical data solutions. The introduction of a transformative platform at a major conference is likely to significantly impact OneMedNet's market position and investor sentiment.
20 Nov
OneMedNet Corporation (ONMD) has announced a significant expansion of its network, leading to a 37% increase in clinical exams and a 38% growth in patient records. This strategic move aims to accelerate the company's subscription revenue strategy, positioning it as a leader in the industry. The network expansion and growth in clinical exams and patient records are likely to significantly enhance future revenue and market positioning.
16 Oct
OneMedNet Corporation has partnered with Palantir Technologies to enhance healthcare AI capabilities. This collaboration aims to leverage Palantir's data analytics platform to improve healthcare data management and patient outcomes. The partnership is expected to drive innovation in healthcare technology, enabling better insights and operational efficiencies for healthcare providers. The partnership with Palantir is likely to significantly enhance OneMedNet's technological capabilities and market positioning in the healthcare sector.
13 Oct
Palantir Technologies is expanding its AI platform's market reach through a new healthcare deal, which could enhance its valuation and competitive positioning in the healthcare sector. This strategic move aims to leverage advanced data analytics and AI capabilities to improve healthcare outcomes and operational efficiencies. The expansion of Palantir's AI platform into healthcare may moderately influence market dynamics and competitive positioning for companies like OneMedNet Corporation.
8 Oct
OneMedNet Corporation (ONMD) has entered a strategic collaboration with Medcase to enhance its capabilities in healthcare AI data management. This partnership aims to leverage advanced AI technologies to improve data interoperability and analytics in the healthcare sector. The collaboration is expected to strengthen ONMD's position in the market by providing innovative solutions that address critical challenges in healthcare data utilization. The collaboration with Medcase is a significant strategic move that could enhance ONMD's competitive positioning and market performance.
6 Oct
OneMedNet Corporation has partnered with Palantir Technologies to enhance artificial intelligence applications in healthcare. This collaboration aims to leverage Palantir's data integration and analytics capabilities to improve patient outcomes and streamline healthcare operations. The partnership is expected to drive innovation in healthcare data management and analytics, positioning OneMedNet as a leader in the AI healthcare space. The partnership with Palantir is a significant strategic move that could enhance OneMedNet's competitive positioning and market presence in the healthcare AI sector.
OneMedNet Corporation has partnered with Palantir Technologies to enhance its healthcare AI and data analytics capabilities. This collaboration aims to leverage Palantir's advanced data integration and analytics tools to improve healthcare outcomes and streamline operations. The partnership is expected to facilitate better data management and insights for healthcare providers, ultimately benefiting patient care. The partnership with Palantir is a significant strategic move that could enhance OneMedNet's competitive position and market performance in the healthcare sector.
25 Aug
OneMedNet Corporation (ONMD) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market dynamics have contributed to its visibility among investors, potentially influencing its stock performance in the near term. Increased trading activity may moderately influence investor sentiment and stock performance.
14 Aug
OneMedNet Corporation (ONMD) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market positioning have contributed to its visibility among investors, indicating potential shifts in market dynamics. Increased trading activity suggests a moderately noticeable influence on market sentiment and investor interest.